

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 1090-26

GHERARDI et al

C# M#

Serial No. 09/423,516

Group Art Unit: 1647

Filed: February 10, 2000

Examiner: Hayes

Date: July 27, 2001

Title: HGF POLYPEPTIDES AND THEIR USE IN THERAPY

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**RESPONSE/AMENDMENT/LETTER**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

**Fees are attached as calculated below:**

Total effective claims after amendment 0 minus highest number  
previously paid for 20 (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment 0 minus highest number  
previously paid for 3 (at least 3) = 0 x \$ 80.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$270.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this  
paper and attachment(s) (\$110.00/1 month; \$390.00/2 months; \$890.00/3 months) \$ 0.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$710.00) \$ 0.00  
☐ Please enter the previously unentered, filed  
☐ Submission attached

**Subtotal \$ 0.00**

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00  
☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: Copy of 6/27/01 Communication from PTO; Copy of Submission filed February 29, 2000 as well as  
paper copy of Sequence Listing filed February 29, 2000 and copy of Feb. 27, 2000 postcard receipt 0.00

**TOTAL FEE ENCLOSED \$ 0.00**


The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which  
should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No.  
14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
BJS:eaw

NIXON & VANDERHYE P.C.  
By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: 

LCM



UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/423,516 02/18/98 GHEPAROI

E 1090-26

EXAMINER

HAYES, R

ART UNIT

PAPER NUMBER

1647

DATE MAILED:

06/27/01

NIXON & VANDERHYE  
1100 NORTH GLEBE ROAD  
9TH FLOOR  
ARLINGTON VA 22201-4714

HM12/0627


Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

DOCKETED

CLT/MATTER # 1090-26  
MAIL DATE 6/27/01  
DUE DATE JULY 27, 2001  
FINAL DEADLINE DEC 27, 2001  
DOCKETED BY MCE/MSS

NIXON & VANDERHYE PC  
2001 JUN 28 AM 11:51



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/423,516			

RECEIVED

AUG 01 2001

TECH CENTER 1600/2900

EXAMINER	
ART UNIT	PAPER NUMBER
	10

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 because 37 CFR 1.821 (a)(2)(c-d) states that each sequence disclosed must appear separately in the "Sequence listing" *and in the text of the description and claims* (i.e., where first mentioned in the specification; e.g., pages 32 & 30). See MPEP 2431. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Any inquiry concerning this communication should be directed to Examiner **Robert C. Hayes**, Art Unit **1647**, whose telephone number is **703-305-3132**.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.


Robert C. Hayes, Ph.D.  
May 22, 2001

GARY L. KUNZ  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600



Serial No.: 09/423,516      Atty: LCM  
Applicant: GHERARDI et al      Date: February 29, 2000  
Client/Matter: 1090-26  
Title: HGF POLYPEPTIDES AND THEIR USE IN THERAPY

Amendment  
Pages Specification, Claims & Abstract  
Claims  
Sheets of Drawings  
Declaration (      Pages)  
Assignment (      Pages) Including Cover  
Priority Document(s)  
Base Issue Fee Transmittal  
Fee (Check)



\$  
Other: **Supplemental IDS, Form PTO-1449 and  
References; Submission of Sequence Listing;  
Paper Copy of Sequence Listing, 3.5 Computer-  
Readable Copy of Sequence Listing**